Kronos Bio Announces Participation in 43rd Annual Cowen Health Care Conference
Kronos Bio, Inc. (Nasdaq: KRON) announced its participation in the 43rd Annual Cowen Health Care Conference, scheduled for March 6-8, 2023, in Boston, Massachusetts.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Kronos Bio, Inc. (Nasdaq: KRON) announced its participation in the 43rd Annual Cowen Health Care Conference, scheduled for March 6-8, 2023, in Boston, Massachusetts. CEO Norbert Bischofberger will speak on the ‘Novel Oncology Targets’ panel on March 7 at 9:10 a.m. ET. The discussion will be available via webcast on the company’s website, with a replay accessible for 30 days post-event.
Kronos Bio focuses on developing cancer treatments, including the CDK9 inhibitor KB-0742 for MYC-amplified solid tumors and lanraplenib for FLT3-mutated acute myeloid leukemia.
Positive
- Participation in a major healthcare conference may enhance visibility and networking opportunities.
- Presentation of innovative oncology targets could attract investor interest and strengthen market position.
Negative
- None.
Details
News Market Reaction – KRON
The recorded move for KRON in the trading session of this news was -0.57%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN MATEO, Calif. and CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced participation in the 43rd Annual Cowen Health Care Conference, taking place March 6-8, 2023, in Boston, Massachusetts.
Kronos Bio President and Chief Executive Officer Norbert Bischofberger, Ph.D., will participate in the “Novel Oncology Targets” panel discussion on Tuesday, March 7, at 9:10 a.m. ET.
The webcast of the panel discussion will be available on the Investors and Media section of the Kronos Bio website at www.kronosbio.com. A replay of the webcast will be archived and available for 30 days following the event.
About Kronos Bio, Inc.
Kronos Bio is a biopharmaceutical company that is advancing two investigational compounds in clinical trials for patients with cancer. The company is developing the CDK9 inhibitor, KB-0742, as a treatment for MYC-amplified solid tumors, and lanraplenib, a next-generation SYK inhibitor, for patients with relapsed/refractory FLT3-mutated acute myeloid leukemia. The company’s scientific focus is on developing medicines that target the dysregulated transcription that is the hallmark of cancer and other serious diseases.
Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass. For more information, visit www.kronosbio.com or follow the company on LinkedIn.
Investors:
Claudia Styslinger
Argot Partners
212-600-1902
kronosbio@argotpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.